Q2 2025 Ginkgo Bioworks Holdings Inc Earnings Call Transcript
Key Points
- Ginkgo Bioworks Holdings Inc (DNA) achieved a $250 million annual run rate cost savings target a quarter early, demonstrating effective cost management.
- The company has a strong cash position with $474 million in cash and cash equivalents and no bank debt, providing a significant margin of safety.
- Cell engineering revenue increased by 8% year-over-year, with a 10% increase in revenue-generating programs, indicating growth in this segment.
- Adjusted EBITDA improved significantly from negative $99 million in Q2 2024 to negative $28 million in Q2 2025, a 72% improvement.
- The launch of new products in the life science tools space, such as automation and reagents, is expected to drive future growth and open new markets.
- The Biosecurity business saw a decrease in revenue guidance from $50 million-plus to $40 million-plus, reflecting challenges in securing international contracts.
- Despite improvements, the company still reported a net loss, highlighting ongoing financial challenges.
- The company faces risks related to excess lease space, which is a cash operating cost not currently contributing to revenue.
- The market for life science tools is currently tough, with potential acquisitions being uncertain due to market conditions.
- There is uncertainty in achieving adjusted EBITDA breakeven by the end of 2026, with significant reliance on revenue growth from new tools and automation offerings.
Good evening. I'm Daniel Marshall, Senior Manager of Communications and Ownership. I'm joined by Jason Kelly, our Co-Founder and CEO; and our new CFO, Steve Coen. Thanks, as always, for joining us. We're looking forward to updating you on our progress.
As a reminder, during the presentation today, we'll be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the SEC to learn more about these risks and uncertainties, including our most recent 10-K.
Today, in addition to updating you on the quarter results, we're going to provide updates on our path towards adjusted EBITDA breakeven and dive deeper into the new deals and launches in Ginkgo's Tools businesses, which continue to establish themselves as critical tools in AI-powered bioengineering. As usual, we'll end with a Q&A session, and I'll take questions from analysts, investors and the public. You can submit those questions to us in advance via X #Ginkgoresults or e-mail investors
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
